Skip to content

21 Day Cumulative Skin Irritation of RUT058-60

Phase 1 21-Day Evaluation of the Cumulative Irritation Potential of RUT058-60 on Abraded and Non-Abraded Skin Sites

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02198963
Enrollment
43
Registered
2014-07-24
Start date
2014-07-31
Completion date
2014-09-30
Last updated
2016-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritation/Irritant

Keywords

Skin irritation potential of RUT058-60.

Brief summary

The purpose of this study is to determine the skin irritation potential of RUT058-60 after repetitive patch application to abraded and non-abraded skin of human subjects.

Detailed description

This Cumulative Irritation Evaluation is designed to determine the skin irritation potential of RUT058-60, after repetitive patch application to abraded and non-abraded skin of healthy human subjects. Abraded skin will be challenged because the Test Product may be used, in practice, on non-intact skin. The primary research objective in this study is determine the skin irritation potential of RUT058-60. This question will be answered based on the observed results acquired evaluating its application to the abraded and non-abraded skin of at least 30 volunteer subjects, on the test product relative to the control readings. A sufficient number of subjects will be recruited into the study to ensure 30 subjects, including both males and females, complete the study. Prior to the first application of test materials, designated skin sites will be abraded using the Tape Stripping Procedure. Occlusive patches will be used to apply approximately 0.02 mL of Test Product, Positive Control and Negative Control to abraded and non-abraded sites on the skin in the scapular region of each subject's back. The irritation potential of the test materials will be determined over the course of a 21-day challenge period on at least 30 subjects. A test material will be applied to the same site, abraded and non-abraded, on each day for 21 days. The six skin sites will be evaluated visually prior to each patch application and following the final patch removal.

Interventions

DRUGHypochlorous acid solution 106 mg/L

test product

DRUG0.1% (w/v) Sodium Lauryl Sulfate

positive control

DRUG0.9% Physiological Saline, USP

negative control

Sponsors

Pulmatrix Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Subjects may be of either sex, at least 18 years of age and of any race * Subjects must be free of tattoos, sunburn, dermatoses, cuts, lesions, or other disorders on the parascapular skin of the back * Subjects must be in good general health, as evidenced by the Subject Confidential Information and Acceptance Criteria and confirmed by screening laboratory evaluations * Subjects must read and sign an Informed Consent Form, Subject Confidential Information and Acceptance Criteria, Authorization to Use and Disclose Protected Health Information Form

Exclusion criteria

* Known allergies to latex (rubber), metals, ink, tape and/or adhesives, soap, hypochlorous acid, sodium lauryl sulfate, physiological Saline * Exposure of the upper back region to antimicrobial agents, medicated soaps, medicated shampoos, medicated lotions, or strong detergents in the 7 days prior to, or during the 3-week test period; or sun-tanning, use of tanning beds, or swimming or soaking in pools or hot tubs * Use of topical or systemic corticosteroid, antihistamine, or anti-inflammatory medications in the 7 days prior to, or during the 3-week test period * A medical diagnosis of a physical condition, such as a current or recent severe illness, asthma, diabetes, hepatitis, an organ transplant, mitral valve prolapse, congenital heart disease, internal prostheses, or any immunocompromised condition, such as AIDS (or HIV positive) * Pregnancy, plans to become pregnant within the pre-test period or test days of the study, or nursing a child. Women cannot be pregnant, as evidenced by a negative urine pregnancy test, or should be of non-childbearing potential; that is, surgically sterile or postmenopausal (amenorrhea for at least 12 months) * Any active skin rashes or breaks in the skin of the parascapular region of the back * Any sunburn or tattoos on the skin of the parascapular region of the back * A currently active skin disease or inflammatory skin condition, including contact dermatitis * Participation in a clinical study in the past 7 days or current participation in another clinical study * Any medical condition or use of any medications that, in the opinion of the Principal Investigator, should preclude participation * Clinical laboratory assessments that are determined by the Principal Investigator to indicate a clinically relevant abnormality and/or an exclusionary medical condition * Unwillingness to fulfill the performance requirements of the study

Design outcomes

Primary

MeasureTime frameDescription
Cumulative Irritation Score of RUT058-60 Hypochlorous Acid Solution (106 mg/L) on Healthy Human Skin21 daysPrimary Analysis After a 23-hour ± 1-hour period of exposure, patches were removed, and the sites evaluated and visually scored for irritancy. The procedures will be repeated on the same test sites an additional twenty times. On each day,mean values, sample sizes, ranges, etc., of the irritation scores, for a total of six configurations, were recorded. Grading Scale for Visual Evaluation of Skin Condition: 0= no evidence of irritation, 1= minimal erythema, barely perceptible, 2= definite erythema, readily visible; minimal edema or minimal papular response, 3= erythema and papules, 4= definite edema, 5= erythema, edema, and papules, 6=' vesicular eruption, 7= strong reaction spreading beyond test site Visual observations of 3, 4, or 5 resulted in discontinuance of product application to that site. Observations of 6 or 7 were considered an adverse event and subject discontinued from the study.

Countries

United States

Participant flow

Recruitment details

Subjects were recruited and screened at a single US center

Participants by arm

ArmCount
RUT058-60 vs Negative and Positve Controls
All subjects who were enrolled, remained compliant and participated in all scheduled visits and received all study material applications were analyzed.
43
Total43

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyAdverse Event1
Overall StudyWithdrawal by Subject6

Baseline characteristics

CharacteristicRUT058-60 vs Negative and Positve Controls
Age, Continuous35 years
STANDARD_DEVIATION 13.3
Race/Ethnicity, Customized
American Indian or Alaska Native
2 participants
Race/Ethnicity, Customized
Asian
0 participants
Race/Ethnicity, Customized
Black or African American
1 participants
Race/Ethnicity, Customized
Latino
2 participants
Race/Ethnicity, Customized
Native Hawaiian or Other Pacific Islander
0 participants
Race/Ethnicity, Customized
Unknown or Not Reported
1 participants
Race/Ethnicity, Customized
White
37 participants
Region of Enrollment
United States
43 participants
Sex: Female, Male
Female
22 Participants
Sex: Female, Male
Male
21 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
5 / 43
serious
Total, serious adverse events
0 / 43

Outcome results

Primary

Cumulative Irritation Score of RUT058-60 Hypochlorous Acid Solution (106 mg/L) on Healthy Human Skin

Primary Analysis After a 23-hour ± 1-hour period of exposure, patches were removed, and the sites evaluated and visually scored for irritancy. The procedures will be repeated on the same test sites an additional twenty times. On each day,mean values, sample sizes, ranges, etc., of the irritation scores, for a total of six configurations, were recorded. Grading Scale for Visual Evaluation of Skin Condition: 0= no evidence of irritation, 1= minimal erythema, barely perceptible, 2= definite erythema, readily visible; minimal edema or minimal papular response, 3= erythema and papules, 4= definite edema, 5= erythema, edema, and papules, 6=' vesicular eruption, 7= strong reaction spreading beyond test site Visual observations of 3, 4, or 5 resulted in discontinuance of product application to that site. Observations of 6 or 7 were considered an adverse event and subject discontinued from the study.

Time frame: 21 days

Population: Each subject had each study material (test, positive and negative controls) applied to separate abraded and non-abraded skin sites

ArmMeasureValue (MEAN)Dispersion
Hypochlorous Acid Solution 106 mg/L-AbradedCumulative Irritation Score of RUT058-60 Hypochlorous Acid Solution (106 mg/L) on Healthy Human Skin1.00 units on a scaleStandard Deviation 0.68
Sodium Lauryl Sulfate (0.1%) -AbradedCumulative Irritation Score of RUT058-60 Hypochlorous Acid Solution (106 mg/L) on Healthy Human Skin2.46 units on a scaleStandard Deviation 0.55
Physiological Saline (0.9%), USP-AbradedCumulative Irritation Score of RUT058-60 Hypochlorous Acid Solution (106 mg/L) on Healthy Human Skin1.34 units on a scaleStandard Deviation 0.44
Hypochlorous Acid Solution 106 mg/L- Non-AbradedCumulative Irritation Score of RUT058-60 Hypochlorous Acid Solution (106 mg/L) on Healthy Human Skin0.58 units on a scaleStandard Deviation 0.33
Sodium Lauryl Sulfate (0.1%)- Non-AbradedCumulative Irritation Score of RUT058-60 Hypochlorous Acid Solution (106 mg/L) on Healthy Human Skin1.84 units on a scaleStandard Deviation 0.58
Physiological Saline (0.9%), USP- Non-AbradedCumulative Irritation Score of RUT058-60 Hypochlorous Acid Solution (106 mg/L) on Healthy Human Skin0.82 units on a scaleStandard Deviation 0.51

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026